Skip to main content

Advertisement

Log in

Controlled substances in hospices after patient death: a cross-sectional survey of Ontario hospices

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Practices related to the handling of controlled substances (CS) in Ontario hospices have not been previously published and therefore, are unknown. Objective The objective of this study was to determine current practices, and policies, standard operating procedures (SOPs) and guidelines related to handling and disposal of CS at hospices across Ontario. Setting This study was a cross-sectional survey of hospices in Ontario. Method A list of all hospices in Ontario, 39 in total, was obtained from Hospice and Palliative Care Ontario. The Director at each hospice was contacted to request contact information on the person most likely to be knowledgeable about handling procedures related to CS. All participants who provided consent were asked to complete a telephone survey composed of 32 questions: 20 multiple-choice and 12 open-ended. Of the 20 multiple-choice, eight requested demographics of the hospice, nine were related to disposal and documentation practices. Main outcome measure Demographic information, disposal practices and patterns of care were summarized and presented as frequencies or means. Responses to open-ended questions were analyzed qualitatively to identify themes related to the handling and disposal of controlled substances in hospices. Results Twelve hospices (12/39; 31%) participated in the survey, 25 did not, and two were ineligible. Two (2/12, 17%) hospices served both pediatric and adult patients while 10 (83%) served adults only; 100% indicated that 76–100% of their patients were on CS at time of death. Eight (67%) had a policy for controlled substances handling, two had policy and SOPs and two had no policies, guidelines or SOPs. Qualitative analysis indicated variability in procedures for obtaining CS (patient’s own supply, other patient’s supply, hospice associated pharmacy), storage and dispensation of CS (location, secure lock, dispensing by staff or family), documentation (dispensing records, double signature, tracking returns and disposal), and disposal of CS (return to pharmacy, disposal at hospice, return to families). Conclusion Although most of the hospices have a policy, guideline or SOP on the handling of CS, there is considerable variation in practice of dispensing CS to patients, documentation and disposal of CS, which may provide an avenue for inappropriate use, abuse or diversion of CS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Fischer B, Pang M, Tyndall M. The opioid death crisis in Canada: crucial lessons for public health. Lancet Public Health. 2019;4(2):e81–2.

    Article  Google Scholar 

  2. Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. The burden of opioid-related mortality in the United States. JAMA Netw Open. 2018;1(2):e180217. https://doi.org/10.1001/jamanetworkopen.2018.0217.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Government of Canada. Updated numbers on opioid-related overdose deaths in Canada - Canada.ca [Internet]. Public Health Agency of Canada. 2019. https://www.canada.ca/en/public-health/news/2019/04/updated-numbers-on-opioid-related-overdose-deaths-in-canada.html. Accessed 11 Nov 2019.

  4. Gomes T, Khuu W, Martins D, Tadrous M, Mamdani MM, Paterson JM, et al. Contributions of prescribed and non-prescribed opioids to opioid related deaths: Population based cohort study in Ontario. Canada. BMJ. 2018;2018:362. https://doi.org/10.1136/bmj.k3207.

    Article  Google Scholar 

  5. Government of Canada. National Report: Apparent opioid-related deaths in Canada - Data Blog - Public Health Infobase | Public Health Agency of Canada. 2019. https://health-infobase.canada.ca/datalab/national-surveillance-opioid-mortality.html#AORD. Accessed 11 Nov 2019.

  6. Health Canada. Framework on Palliative Care in Canada. 2018 https://www.canada.ca/en/health-canada/services/health-care-system/reports-publications/palliative-care/framework-palliative-care-canada.html#p1.1. Accessed 13 Nov 2019.

  7. World Health Organization. WHO | WHO Definition of Palliative Care . https://www.who.int/cancer/palliative/definition/en/. Accessed 12 Feb 2020.

  8. Health Quality Ontario. Palliative Care at the End of Life: Report Update 2019. https://www.hqontario.ca/Portals/0/documents/system-performance/palliative-care-report-2019-en.pdf. Accessed 2 Dec 2019.

  9. British Columbia Ministry of Health, Doctors of BC, BC Cancer Agency. Palliative care for the patient with incurable cancer or advanced disease Part 2: Pain and Symptom Management. 2017. www.bc-cpc.ca/cpc/symptom-management-guidelines/. Accessed 13 Nov 2019.

  10. Mejin M, Keowmani T, Abdul Rahman S, Liew J, Lai J, Chua M, et al. Prevalence of pain and treatment outcomes among cancer patients in a malaysian palliative care unit. Pharm Pract (Granada). 2019;17(1):1–9.

    Article  Google Scholar 

  11. Speer ND, Dioso J, Casner PR. Costs and implications of discarded medication in hospice. J Palliat Med. 2013;16(8):975–8.

    Article  Google Scholar 

  12. National Hospice and Palliative Care Organization. NHPCO Facts and Figures: Hospice Care in America. 2012. https://www.medpagetoday.com/upload/2012/1/16/2011_Facts_Figures.pdf. Accessed 13 Nov 2019.

  13. Wood H, Dickman A, Star A, Boland JW. Updates in palliative care—overview and recent advancements in the pharmacological management of cancer pain. Clin Med J (Lond). 2018;18(1):17–22.

    Google Scholar 

  14. Durán-Crane A, Laserna A, López-Olivo MA, Cuenca JA, Díaz DP, Cardenas YR, et al. Clinical practice guidelines and consensus statements about pain management in critically ill end-of-life patients: a systematic review. Crit Care Med. 2019;47:1619–26.

    Article  Google Scholar 

  15. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):58–68.

    Article  Google Scholar 

  16. World Health Organization. WHO | WHO’s cancer pain ladder for adults. WHO. 2013. https://www.who.int/cancer/palliative/painladder/en/. Accessed 13 Nov 2019.

  17. Madadi P, Hildebrandt D, Lauwers AE, Koren G. Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in ontario. Canada. PLoS One. 2013;8(4):e60600. https://doi.org/10.1371/journal.pone.0060600.

    Article  CAS  PubMed  Google Scholar 

  18. Blackhall LJ, Alfson ED, Barclay JS. Screening for substance abuse and diversion in virginia hospices. J Palliat Med. 2013;16(3):237–42.

    Article  Google Scholar 

  19. Kneuss TG, Protus BM, Lovell AG, Kullgren JG. State legislation to prevent diversion of opioids in hospice programs. J Hosp Palliat Nurs. 2019;21(5):365–72.

    Article  Google Scholar 

  20. Government of Canada, Minister of Justice. Part III: Disposal of Controlled Substances. Controlled Drugs and Substances Act 2015.

  21. Canadian Hospice Palliative Care Association, Canadian Home Care Association. The Pan-Canadian Gold Standard for Palliative Home Care Toward Equitable Access to High Quality Hospice Palliative and End-of-Life Care at Home. Ottawa, ON: Canadian Hospice Palliative Care Association, 2006. https://www.acsp.net/product/the-pan-canadian-gold-standard-for-palliative-home-care-download-anglais/ Accessed 14 Feb 2020.

  22. Canadian Hospice Palliative Care Association. A model to guide hospice palliative care. Ottawa, ON: Canadian Hospice Palliative Care Association 2013. https://www.chpca.ca/wp-content/uploads/2019/12/norms-of-practice-eng-web.pdf Accessed 14 Feb 2020.

  23. Government of Canada. Controlled Drugs and Substances Act. 1996. https://laws-lois.justice.gc.ca/eng/acts/c-38.8/ Accessed 14 Feb 2020.

  24. Ali MM, Henke RM, Mutter R, O’Brien PL, Cutler E, Mazer-Amirshahi M, et al. Family member opioid prescriptions and opioid use disorder. Addict Behav. 2019;95:58–63.

    Article  Google Scholar 

  25. McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav. 2007;32(3):562–75.

    Article  Google Scholar 

  26. Ontario College of Pharmacists. Destruction of Narcotics, Controlled Drugs, and Targeted Substances. https://www.ocpinfo.com/practice-education/practice-tools/fact-sheets/destruction/. Accessed 12 Feb 2020.

  27. Hospice and Palliative Nurses Association. Position statement: medication safety in hospice and palliative care settings. J Hosp Palliat Nurs. 2019;21:E24–7.

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Hospice and Palliative Care Ontario for their assistance with this study.

Funding

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tejal Patel.

Ethics declarations

Conflicts of interest

The authors declare they have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patel, T., Hasan, S., Chang, F. et al. Controlled substances in hospices after patient death: a cross-sectional survey of Ontario hospices. Int J Clin Pharm 42, 1344–1353 (2020). https://doi.org/10.1007/s11096-020-01097-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-020-01097-y

Keywords

Navigation